Smallpox Vaccine Potency Testing

The Centers for Disease Control and Prevention intends to award a sole source firm fixed price purchase order to Sanofi Pasteur Biologics, LLC for the purchase of services to perform a plaque titration to quantify the titer of Wetvax for the CDC smallpox stability program. These services will assist the laboratory by ensuring that potency testing is conducted using FDA qualified and validated vaccinia based potency assay on samples of Wetvax. These services will additionally help the laboratory in determining the characteristics of each of the lots of vaccine, including the final titer in Plaque Forming units per milliliter and the Lot Titer. Sanofi Pasteur is the only validated and qualified potency test accepted by the FDA to perform a plaque titration to quantify the titer of Wetvax for the CDC smallpox stability program. This contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b) (SAP) and 10 U.S.C. 2304(c)(1). Interested persons may identify their interest and capability to respond to the requirement or submit proposals. This notice of intent is not a request for competitive quotations; however, all quotations/responses received within five (5) days of the issuance of this notice will be considered by the government. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to contract specialist at contact@example.gov by COB 9 May 2017.